Stock Events

Stock Events

Abeona Therapeutics 

0
104
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q1 2026
Next
-0.29
-0.26
-0.23
-0.2
Expected EPS
-0.19621144048
Actual EPS
N/A

Financials

1,197.47%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
4.96MRevenue
59.38MNet Income

Analyst Ratings

15.18Average Price Target
The highest estimate is 15.18.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PCJP.STU. It's not an investment recommendation.
Apple
16
AAPL
NVIDIA
16
NVDA
Netflix
14
NFLX
Walt Disney Co)
14
DIS

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap29.4B
Biogen focuses on developing therapies for neurological and neurodegenerative diseases, directly competing with Abeona's gene therapy approach for similar disorders.
Pfizer
PFE
Mkt Cap137.76B
Pfizer has a broad portfolio including gene therapies targeting rare diseases, overlapping with Abeona's focus areas.
Sangamo Therapeutics
SGMO
Mkt Cap30.66M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing in the same space as Abeona for genetic disorders.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for rare diseases, directly competing with Abeona's rare disease focus.
Ultragenyx Pharmaceutical
RARE
Mkt Cap3.33B
Ultragenyx Pharmaceutical targets rare and ultra-rare diseases with its drug development, similar to Abeona's focus.
Sarepta Therapeutics
SRPT
Mkt Cap2B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics and gene therapy for rare diseases, competing with Abeona's gene therapy approach.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals engages in developing therapies for treating cystic fibrosis and other serious diseases, competing in the rare disease market with Abeona.
Novo Nordisk
NVO
Mkt Cap218.94B
Novo Nordisk focuses on a broad range of treatments including for rare diseases, potentially competing with Abeona in the gene therapy and rare disease market.

About

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.
Show more...
CEO
Mr. Michael Amoroso
Employees
76
Country
United States
ISIN
US00289Y1073

Listings

F
DE
PCJ.F
STU
DE
PCJ.STU
STU
DE
PCJP.STU
BOATS
BOATS
ABEO.BOATS

0 Comments

Share your thoughts

FAQ

What is Abeona Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Abeona Therapeutics stocks are traded under the ticker PCJP.STU.
When is the next Abeona Therapeutics earnings date?▼
Abeona Therapeutics is going to release the next earnings report on August 12, 2026.
What were Abeona Therapeutics earnings last quarter?▼
PCJP.STU earnings for the last quarter are -0.26 EUR per share, whereas the estimation was -0.29 EUR resulting in a +10.45% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Abeona Therapeutics revenue for the last year?▼
Abeona Therapeutics revenue for the last year amounts to 4.96M EUR.
What is Abeona Therapeutics net income for the last year?▼
PCJP.STU net income for the last year is 59.38M EUR.
How many employees does Abeona Therapeutics have?▼
As of July 14, 2026, the company has 76 employees.
In which sector is Abeona Therapeutics located?▼
Abeona Therapeutics operates in the Health & Wellness sector.
When did Abeona Therapeutics complete a stock split?▼
Abeona Therapeutics has not had any recent stock splits.
Where is Abeona Therapeutics headquartered?▼
Abeona Therapeutics is headquartered in New York, United States.